新型缺血性卒中遗传风险评分在心血管代谢疾病患者中的临床应用
本研究基于5项临床试验中51 288例欧洲血统受试者,验证由32个单核苷酸多态性构成的遗传风险评分(GRS)对缺血性卒中的独立预测价值。中位随访2.5年共发生960例缺血性卒中,校正临床风险因素后GRS最高三分位组风险显著升高(校正HR 1.24,95%CI 1.05-1.45),在房颤且CHA2DS2-VASc评分2分的患者中高遗传风险者卒中风险增加4倍。
要点
- 32-SNP GRS是心血管代谢疾病患者缺血性卒中的独立预测因子(P趋势=0.009)。
- GRS最高三分位组校正HR 1.24(95%CI 1.05-1.45),中三分位组1.15(0.98-1.36)。
- 房颤且CHA2DS2-VASc评分2分者,高遗传风险卒中风险增加4倍。
核心结论
- 在广泛心血管代谢疾病人群中,32-SNP GRS是缺血性卒中的强独立预测因子。
- 房颤且CHA2DS2-VASc评分较低者,GRS可识别出卒中风险与更高CHA2DS2-VASc评分相当的患者。
研究设计与样本
- 基于ENGAGE AF-TIMI 48、SOLID-TIMI 52、SAVOR-TIMI 53、PEGASUS-TIMI 54和FOURIER五项试验的欧洲血统受试者。
- 共纳入51 288例受试者,中位随访2.5年,960例发生缺血性卒中。
- 使用32个与缺血性卒中相关的单核苷酸多态性计算GRS并划分三分位,采用Cox模型校正临床风险因素。
主要发现
- 校正临床风险因素后,GRS升高与缺血性卒中风险增加独立相关(P趋势=0.009)。
- 与GRS最低三分位相比,中三分位校正HR 1.15(95%CI 0.98-1.36),最高三分位校正HR 1.24(95%CI 1.05-1.45)。
- 亚组分析显示GRS在一级预防队列中表现更强,最高vs最低三分位校正HR 1.27(95%CI 1.04-1.53),既往卒中者校正HR 1.06(95%CI 0.81-1.41)。
- 探索性分析中,房颤且CHA2DS2-VASc评分2分者,高遗传风险卒中风险增加4倍,绝对风险相当于CHA2DS2-VASc评分3分者。
临床怎么用
- GRS可作为心血管代谢疾病患者缺血性卒中的独立风险分层工具。
- 对房颤且CHA2DS2-VASc评分较低(如2分)者,GRS可能帮助识别需强化抗凝等预防策略的高危患者。
局限性
- 仅纳入欧洲血统受试者,结论外推至其他种族需谨慎。
- 数据来源于临床试验人群,可能不能完全代表真实世界患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genome-wide association studies have identified single-nucleotide polymorphisms that are associated with an increased risk of stroke. We sought to determine whether a genetic risk score (GRS) could identify subjects at higher risk for ischemic stroke after accounting for traditional clinical risk factors in 5 trials across the spectrum of cardiometabolic disease. METHODS: Subjects who had consented for genetic testing and who were of European ancestry from the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation), SOLID-TIMI 52 (Stabilization of Plaques Using Darapladib), SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus), PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin), and FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) trials were included in this analysis. A set of 32 single-nucleotide polymorphisms associated with ischemic stroke was used to calculate a GRS in each patient and identify tertiles of genetic risk. A Cox model was used to calculate hazard ratios for ischemic stroke across genetic risk groups, adjusted for clinical risk factors. RESULTS: In 51 288 subjects across the 5 trials, a total of 960 subjects had an ischemic stroke over a median follow-up period of 2.5 years. After adjusting for clinical risk factors, a higher GRS was strongly and independently associated with increased risk for ischemic stroke (P trend=0.009). In comparison with individuals in the lowest third of the GRS, individuals in the middle and top tertiles of the GRS had adjusted hazard ratios of 1.15 (95% CI, 0.98-1.36) and 1.24 (95% CI 1.05-1.45) for ischemic stroke, respectively. Stratification into subgroups revealed that the performance of the GRS appeared stronger in the primary prevention cohort with an adjusted hazard ratio for the top versus lowest tertile of 1.27 (95% CI, 1.04-1.53), in comparison with an adjusted hazard ratio of 1.06 (95% CI, 0.81-1.41) in subjects with previous stroke. In an exploratory analysis of patients with atrial fibrillation and CHA2DS2-VASc score of 2, high genetic risk conferred a 4-fold higher risk of stroke and an absolute risk equivalent to those with CHA2DS2-VASc score of 3. CONCLUSIONS: Across a broad spectrum of subjects with cardiometabolic disease, a 32-single-nucleotide polymorphism GRS was a strong, independent predictor of ischemic stroke. In patients with atrial fibrillation but lower CHA2DS2-VASc scores, the GRS identified patients with risk comparable to those with higher CHA2DS2-VASc scores.
引用
- Marston NA, Patel PN, Kamanu FK, et al. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2020. PMID: 33185476. doi:10.1161/CIRCULATIONAHA.120.051927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。